Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Where GI practices are struggling, succeeding (Becker’s GI & Endoscopy)
- Physician shortage and private equity: the ruin of U.S. health care (KevinMD)
- Why leading physicians will move to concierge medicine in 2026 with Greg Grant of Specialdocs (Physicians Practice)
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy (Nature)
- Stiffer colon could signal risk of early-onset colorectal cancer (Medical Xpress)
- Successful GI Sign-off Protocol Incorporates Primary Care Feedback (GI & Endoscopy News)
- Earlier and More Intensive Advanced Therapy Use Fails to Improve 10-Year Crohn’s Outcomes (Docwire News)
- CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1 (HIT Consultant)
